155 related articles for article (PubMed ID: 22774997)
1. Thromboembolism prophylaxis in medical inpatients: effect on outcomes and costs.
Baser O; Sengupta N; Dysinger A; Wang L
Am J Manag Care; 2012 Jun; 18(6):294-302. PubMed ID: 22774997
[TBL] [Abstract][Full Text] [Related]
2. Pharmacologic prophylaxis for venous thromboembolism and 30-day outcomes among older patients hospitalized with heart failure: an analysis from the ADHERE national registry linked to Medicare claims.
Kociol RD; Hammill BG; Hernandez AF; Klaskala W; Mills RM; Curtis LH; Fonarow GC
Clin Cardiol; 2011 Nov; 34(11):682-8. PubMed ID: 22057910
[TBL] [Abstract][Full Text] [Related]
3. Pharmacoeconomic analysis of bemiparin and enoxaparin as prophylaxis for venous thromboembolism in total knee replacement surgery.
Honorato J; Gómez-Outes A; Navarro-Quilis A; Martínez-González J; Rocha E; Planès A
Pharmacoeconomics; 2004; 22(13):885-94. PubMed ID: 15329033
[TBL] [Abstract][Full Text] [Related]
4. Optimal dosing of bemiparin as prophylaxis against venous thromboembolism in surgery for cancer: an audit of practice.
Balibrea JL; Altimiras J; Larruzea I; Gómez-Outes A; Martínez-González J; Rocha E;
Int J Surg; 2007 Apr; 5(2):114-9. PubMed ID: 17448976
[TBL] [Abstract][Full Text] [Related]
5. Real-World Comparative Effectiveness and Cost Comparison of Thromboprophylactic Use of Enoxaparin versus Unfractionated Heparin in 376,858 Medically Ill Hospitalized US Patients.
Veeranki SP; Xiao Z; Levorsen A; Sinha M; Shah BR
Am J Cardiovasc Drugs; 2021 Jul; 21(4):443-452. PubMed ID: 33313988
[TBL] [Abstract][Full Text] [Related]
6. Impact of thromboprophylaxis across the US acute care setting.
Huang W; Anderson FA; Rushton-Smith SK; Cohen AT
PLoS One; 2015; 10(3):e0121429. PubMed ID: 25816146
[TBL] [Abstract][Full Text] [Related]
7. An economic evaluation of the costs and benefits of heparin rationalisation in a hospital pharmacy.
Reeves P; Cooke J; Lloyd A; Hutchings A
Pharm World Sci; 2004 Jun; 26(3):160-8. PubMed ID: 15230364
[TBL] [Abstract][Full Text] [Related]
8. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Candeloro M; De Tursi M; Russi I; Rutjes AW
Cochrane Database Syst Rev; 2016 Dec; 12(12):CD008500. PubMed ID: 27906452
[TBL] [Abstract][Full Text] [Related]
9. Extended thromboprophylaxis with low-molecular-weight heparins after hospital discharge in high-risk surgical and medical patients: a review.
Huo MH; Muntz J
Clin Ther; 2009 Jun; 31(6):1129-41. PubMed ID: 19695383
[TBL] [Abstract][Full Text] [Related]
10. Economic evaluation of enoxaparin as prophylaxis against venous thromboembolism in seriously ill medical patients: a US perspective.
de Lissovoy G; Subedi P
Am J Manag Care; 2002 Dec; 8(12):1082-8. PubMed ID: 12500884
[TBL] [Abstract][Full Text] [Related]
11. Venous thromboembolism prophylaxis in medical inpatients: a retrospective chart review.
Rahim SA; Panju A; Pai M; Ginsberg J
Thromb Res; 2003; 111(4-5):215-9. PubMed ID: 14693166
[TBL] [Abstract][Full Text] [Related]
12. Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy.
Di Nisio M; Porreca E; Otten HM; Rutjes AW
Cochrane Database Syst Rev; 2014 Aug; (8):CD008500. PubMed ID: 25171736
[TBL] [Abstract][Full Text] [Related]
13. Prophylaxis against venous thromboembolism in hospitalized medically ill patients.
Pendergraft T; Liu X; Edelsberg J; Phatak H; Vera-Llonch M; Liu LZ; Oster G
Circ Cardiovasc Qual Outcomes; 2013 Jan; 6(1):75-82. PubMed ID: 23300270
[TBL] [Abstract][Full Text] [Related]
14. Retrospective database analysis of the prevention of venous thromboembolism with low-molecular-weight heparin in acutely III medical inpatients in community practice.
McGarry LJ; Thompson D
Clin Ther; 2004 Mar; 26(3):419-30. PubMed ID: 15110135
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of enoxaparin as prophylaxis against venous thromboembolic complications in acutely ill medical inpatients: modelling study from the hospital perspective in Germany.
Schädlich PK; Kentsch M; Weber M; Kämmerer W; Brecht JG; Nadipelli V; Huppertz E
Pharmacoeconomics; 2006; 24(6):571-91. PubMed ID: 16761905
[TBL] [Abstract][Full Text] [Related]
16. Compression stockings in addition to low-molecular-weight heparin to prevent venous thromboembolism in surgical inpatients requiring pharmacoprophylaxis: the GAPS non-inferiority RCT.
Shalhoub J; Lawton R; Hudson J; Baker C; Bradbury A; Dhillon K; Everington T; Gohel MS; Hamady Z; Hunt BJ; Stansby G; Warwick D; Norrie J; Davies AH
Health Technol Assess; 2020 Dec; 24(69):1-80. PubMed ID: 33275096
[TBL] [Abstract][Full Text] [Related]
17. Venous thromboprophylaxis in gastrointestinal bleeding.
Malhotra N; Chande N
Can J Gastroenterol Hepatol; 2015 Apr; 29(3):145-8. PubMed ID: 25855878
[TBL] [Abstract][Full Text] [Related]
18. The effect of physician educational intervention on venous thromboembolism pharmacological prophylaxis in medical inpatients from the respiratory department: a retrospective cohort study.
Wang H; Pan Y; Chen T; Chen L; Lv H; Chen E; Qu J; Tang W; Xu W; Lu Y
Ann Palliat Med; 2020 Nov; 9(6):3966-3975. PubMed ID: 33302659
[TBL] [Abstract][Full Text] [Related]
19. Venous thromboembolism prophylaxis and clinical consequences in medically ill patients.
Baser O; Liu X; Phatak H; Wang L; Mardekian J; Kawabata H; Petersel D; Hamilton M; Ramacciotti E
Am J Ther; 2013; 20(2):132-42. PubMed ID: 23466619
[TBL] [Abstract][Full Text] [Related]
20. Venous thromboembolism prophylaxis in hospitalized heart failure patients.
Jois-Bilowich P; Michota F; Bartholomew JR; Glauser J; Diercks D; Weber J; Fonarow GC; Emerman CL; Peacock WF;
J Card Fail; 2008 Mar; 14(2):127-32. PubMed ID: 18325459
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
